Freja K. Ekman

This paper demonstrates an automated, high-throughput platform for manufacturing gene-edited hematopoietic stem and progenitor cells (geHSPCs) with preserved function and in vivo engraftment capacity.

This paper engineers hematopoietic stem and progenitor cells to express CD4 on red blood cells, creating viral traps to neutralize HIV-1.

The paper introduces TFU72, a potent DNA-PKcs inhibitor that significantly enhances HDR gene editing efficiency while mitigating genotoxic side effects.

This study identifies an RNA-mediated DNA melting mechanism in CRISPR-Cas9 using simulations and experiments, showing RNA bases intercalate to promote strand separation.

This paper develops small molecule-inducible EPO receptors to enable erythropoiesis without recombinant EPO, reducing costs and improving scalability of RBC manufacturing.